共 50 条
- [11] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMAHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500Sanchez, R. GarciaSaldana, R.Caparros, I.Gallardo, A.Garcia-Delgado, R.Rosell, A.Campos, A.de Llano, M. P. QueipoPerez, I.Moreno, M. J.Del Castillo, S.De la Torre, S.Ramirez, G.
- [12] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant DataBIOMED RESEARCH INTERNATIONAL, 2018, 2018Li, ShuoMeng, Xiang-YuMaman, Souraka Tapara DramaniXiao, Yong-NongLi, Sheng
- [13] Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myelomaCANCER MEDICINE, 2023, 12 (07): : 8005 - 8017Richter, JoshuaLin, Peggy L.Garcia-Horton, VivianaGuyot, PatriciaSingh, ErinZhou, Zheng-YiSievert, MarkTaiji, Riley
- [14] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Yee, Andrew J.Nadeem, OmarRosenblatt, JacalynBianchi, GiadaO'Donnell, ElizabethBranagan, Andrew R.Harrington, Cynthia C.Agyemang, Emerentia A.Gammon, Marilyn T.Lively, Kathleen J.Packer, Lisette A.Bernstein, Zachary S.Lyons, Rebecca T.Riadi, ManalRowell, Sean M.Mcvey, CailinGoguen, Amy C.Horick, Nora K.Richardson, Paul G.Raje, Noopur S.
- [15] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaBLOOD, 2024, 144 : 7052 - 7053Xu, JiadaiLiu, Peng
- [16] Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, plus /- bortezomib, in patients with relapsed/refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Kaufman, Jonathan L.Baz, Rachid C.Harrison, Simon J.Quach, HangHo, Shir-JingVangsted, Annette J.Moreau, PhilippeGibbs, Simon D. J.Salem, Ahmed H.Coppola, SherylRoss, Jeremy A.Masud, Abdullah A.Westrup, SallyVue, JennyMaciag, Paulo CesarBueno, OrlandoBahlis, Nizar J.
- [17] A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S157Richter, JoshuaLin, PeggyGarcia-Horton, VivianaGuyot, PatriciaSingh, ErinZhou, Zheng-YiSievert, Mark
- [18] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Cerchione, ClaudioNappi, DavideCangini, DeliaRonconi, SoniaCeccolini, MichelaMusuraca, GerardoMartinelli, Giovanni
- [19] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myelomaBLOOD, 2007, 110 (11) : 128A - 128AWeber, DonnaKnight, RobertChen, ChristineSpencer, AndrewYu, ZhinuanZeldis, JeromeOlesnyckyj, MartaDimopoulos, Meletios
- [20] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus DexamethasoneBLOOD, 2016, 128 (22)Avet-Loiseau, HerveCasneuf, TinekeChiu, ChristopherLaubach, Jacob P.Lee, Je-JungMoreau, PhilippePlesner, TorbenNahi, HarethKhokhar, Nushmia Z.Qi, MingSchecter, JordanCarlton, VictoriaQin, XiangLiu, KevinWu, KaidaZhuang, Sen H.Ahmadi, TahamtanSasser, A. KateSan-Miguel, Jesus